Related references
Note: Only part of the references are listed.Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Testing in a Prespecified Subgroup and the Intent-to-Treat Population
Mark D. Rothmann et al.
DRUG INFORMATION JOURNAL (2012)
Randomized Phase II Trial Designs With Biomarkers
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A two-stage Bayesian design for co-development of new drugs and companion diagnostics
Stella Wanjugu Karuri et al.
STATISTICS IN MEDICINE (2012)
Clinical trials for predictive medicine
Richard Simon
STATISTICS IN MEDICINE (2012)
A general inefficacy interim monitoring rule for randomized clinical trials
Boris Freidlin et al.
CLINICAL TRIALS (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
